Waleed H. Hassanein - Sep 1, 2023 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
President & CEO, Director
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Sep 1, 2023
Transactions value $
-$511,920
Form type
4
Date filed
9/6/2023, 04:31 PM
Previous filing
Aug 3, 2023
Next filing
Nov 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Sale -$4.13K -63 -0.01% $65.63 537K Sep 1, 2023 Direct F1
transaction TMDX Common Stock Sale -$138K -2.05K -0.38% $67.35 535K Sep 1, 2023 Direct F1, F2
transaction TMDX Common Stock Sale -$295K -4.31K -0.81% $68.55 530K Sep 1, 2023 Direct F1, F3
transaction TMDX Common Stock Sale -$74.6K -1.08K -0.2% $68.95 529K Sep 1, 2023 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 14, 2022.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $66.85 to $67.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $67.85 to $68.845, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $68.85 to $69.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 Includes 37,332 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.